Category: Cardiac Rhythm Management
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival Boston Scientific over cardiac rhythm management technology.
Arrhythmia Research Technology's signal-averaged electrocardiogram outperforms other ECGs, according to an NIH-funded multi-center study.
Arrhythmia Research Technology's (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.
Endosense touts the safety & effectiveness of its force-sensing ablation catheter at the annual meeting of the Heart Rhythm Society.
Geneva-based Endosense's proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meeting.
Sorin plans an immediate launch for its Smartview remote patient monitoring system now that the FDA has approved the device for the Italian medical device maker's Paradym cardiac rhythm therapy devices.
Sorin Group (BIT:SRN) said it's beginning an immediate launch for the Smartview remote patient monitoring system now that it has FDA approval in hand for the system.
The Italian cardiovascular device maker said the federal watchdog agency OK'd the Smartview system for use with its Paradym RF cardiac rhythm therapy devices.
Patients with Sorin's dual-chamber implantable cardiac defibrillators show lower rates of inappropriate shocks, according to study data presented at the annual Heart Rhythm Society meeting last week.
Patients with Sorin Group (BIT:SRN) dual-chamber implantable cardioverter defibrillators had significantly fewer inappropriate shocks than patients with standard single-chamber devices, according to new clinical data.
Boston Scientific touts data showing 9-to-13-year battery life for its cardiac rhythm management devices at the annual meeting of the Heart Rhythm Society.
Recent study data proves longer battery life of Boston Scientific's (NYSE:BSX) implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators, helping keep patients out of the hospital and reduce risk of infections and complications, the company claimed last week.
Medtronic says it plans use data from a study of biventricular pacing of the heart's 2 lower chambers to back an expaned indication for its cardiac rhythm therapy devices.
Medtronic (NYSE:MDT) plans to use new study results to ask the FDA to expand the indication for its cardiac resynchronization therapy devices, to include patients with atrioventricular block and left ventricular systolic dysfunction.